G1 Therapeutics Inc. (GTHX)
NASDAQ: GTHX
· Real-Time Price · USD
7.16
0.01 (0.14%)
At close: Sep 17, 2024, 7:56 PM
0.14% (1D)
| Bid | 7.14 |
| Market Cap | 377.75M |
| Revenue (ttm) | 58.2M |
| Net Income (ttm) | -44.77M |
| EPS (ttm) | -0.86 |
| PE Ratio (ttm) | -8.325581395348838 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 7.16 |
| Volume | 1,097,310 |
| Avg. Volume (20D) | 2,229,441 |
| Open | 7.15 |
| Previous Close | 7.15 |
| Day's Range | 7.14 - 7.16 |
| 52-Week Range | 1.08 - 7.19 |
| Beta | 1.68 |
About GTHX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol GTHX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for GTHX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts9 months ago
G1 Therapeutics shares are trading higher after th...
Unlock content with
Pro Subscription
10 months ago
G1 Therapeutics shares are trading lower after the company's PRESERVE 2 Phase 3 trial of Trilaciclib did not achieve statistical significance in the primary endpoint of overall survival.